CHARM Therapeutics

CHARM Therapeutics is a clinical-stage biotechnology company applying 3D deep learning to small molecule drug discovery.

Its proprietary platform uses protein-ligand co-folding algorithms to predict binding interactions and identify candidates against difficult-to-drug targets.

CHARM's pipeline focuses primarily on oncology, including a menin inhibitor programme for acute myeloid leukaemia, with additional applications in infectious disease through a collaboration with the Bill and Melinda Gates Foundation targeting tuberculosis.